Evoke Pharma (EVOK) Net Margin (2020 - 2025)
Historic Net Margin for Evoke Pharma (EVOK) over the last 6 years, with Q3 2025 value amounting to 26.99%.
- Evoke Pharma's Net Margin rose 224600.0% to 26.99% in Q3 2025 from the same period last year, while for Sep 2025 it was 36.23%, marking a year-over-year increase of 351000.0%. This contributed to the annual value of 52.22% for FY2024, which is 981900.0% up from last year.
- According to the latest figures from Q3 2025, Evoke Pharma's Net Margin is 26.99%, which was up 224600.0% from 41.87% recorded in Q2 2025.
- Evoke Pharma's 5-year Net Margin high stood at 26.99% for Q3 2025, and its period low was 2997.78% during Q1 2021.
- Its 5-year average for Net Margin is 374.69%, with a median of 165.1% in 2023.
- Its Net Margin has fluctuated over the past 5 years, first tumbled by 2000000000bps in 2021, then surged by 24782400bps in 2022.
- Quarter analysis of 5 years shows Evoke Pharma's Net Margin stood at 463.81% in 2021, then surged by 51bps to 226.43% in 2022, then soared by 48bps to 118.58% in 2023, then soared by 70bps to 36.05% in 2024, then grew by 25bps to 26.99% in 2025.
- Its Net Margin was 26.99% in Q3 2025, compared to 41.87% in Q2 2025 and 42.41% in Q1 2025.